Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 indb/dbmice (奥美拉唑改善唾液素-4 对db/db小鼠的减肥与降糖作用)*-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 indb/dbmice (奥美拉唑改善唾液素-4 对db/db小鼠的减肥与降糖作用)*

Published:2013-04-26 Issue:2 Volume:5 Page:163-171
ISSN:1753-0393
Container-title:Journal of Diabetes
language:en
Short-container-title:

Author:

Patel Vishal,Joharapurkar Amit,Gandhi Tejal,Patel Kirti,Dhanesha Nirav,Kshirsagar Samadhan,Dhote Vipin,Detroja Jaysukh,Bahekar Rajesh,Jain Mukul

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1753-0407.2012.00227.x/fullpdf

Reference37 articles.

1. Global and societal implications of the diabetes epidemic;Zimmet;Nature,2001

2. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group;Matthews;Diabet Med,1998

3. The epidemiology of obesity: The size of the problem;James;J Intern Med,2008

4. Management of type 2 diabetes: New and future developments in treatment;Tahrani;Lancet,2011

5. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes;Nielsen;Regul Pept,2004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liraglutide improves hepatic insulin resistance via the canonical Wnt signaling pathway;Molecular Medicine Reports;2018-03-14

2. Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia;Biomedicine & Pharmacotherapy;2018-02

3. Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition;Chemico-Biological Interactions;2018-02

4. Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus;Endocrine Connections;2018-01

5. Gastrin - A Potential Predictor of Response to Incretin Therapy in Diabetes Type 2 Patients;Endocrine, Metabolic & Immune Disorders - Drug Targets;2017-11-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3